Neither of Cynata Therapeutics Ltd.’s pivotal trials for its Cymerus stem cell platform met the primary endpoints, with no statistically significant differences between active and control groups on primary or key secondary efficacy measures, CEO Kilian Kelly told investors during a June 22 conference call.

BioWorld covers the Trump administration’s latest policy decisions and actions affecting the life sciences sector, as well as their impacts across the globe.